Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Medtronic
Moodys
Merck
Colorcon

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR ETELCALCETIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Etelcalcetide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01134549 ↗ Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers Completed Nucleus Network Ltd Phase 1 2010-06-09 The purpose of this study is to characterize the safety and tolerability of etelcalcetide in healthy young males.
NCT01134549 ↗ Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers Completed KAI Pharmaceuticals Phase 1 2010-06-09 The purpose of this study is to characterize the safety and tolerability of etelcalcetide in healthy young males.
NCT01134562 ↗ Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Completed KAI Pharmaceuticals Phase 1 2010-09-07 The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.
NCT01254565 ↗ Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Completed KAI Pharmaceuticals Phase 2 2011-02-20 The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyroidism (HPT).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Etelcalcetide

Condition Name

Condition Name for Etelcalcetide
Intervention Trials
Secondary Hyperparathyroidism 8
Hyperparathyroidism, Secondary 7
Chronic Kidney Disease 3
Chronic Kidney Disease Mineral and Bone Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Etelcalcetide
Intervention Trials
Hyperparathyroidism 18
Hyperparathyroidism, Secondary 18
Neoplasm Metastasis 14
Renal Insufficiency, Chronic 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Etelcalcetide

Trials by Country

Trials by Country for Etelcalcetide
Location Trials
United States 162
Spain 27
China 21
Canada 21
Australia 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Etelcalcetide
Location Trials
California 10
Texas 9
New York 8
Colorado 7
Louisiana 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Etelcalcetide

Clinical Trial Phase

Clinical Trial Phase for Etelcalcetide
Clinical Trial Phase Trials
Phase 3 9
Phase 2 5
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Etelcalcetide
Clinical Trial Phase Trials
Completed 14
Recruiting 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Etelcalcetide

Sponsor Name

Sponsor Name for Etelcalcetide
Sponsor Trials
Amgen 13
KAI Pharmaceuticals 5
Nucleus Network Ltd 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Etelcalcetide
Sponsor Trials
Industry 18
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Express Scripts
McKesson
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.